medRxiv preprint doi: https://doi.org/10.1101/2023.12.07.23299640; this version posted November 1, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

perpetuity. It is made available under a CC-BY 4.0 International license .

Reward circuit function and treatment outcome following vALIC deep brain stimulation in treatment-resistant depression

- 3
- 4 N. Runia^{*,a,b†}, MSc, L.A. van de Mortel^{*,a,b†}, MSc, C. L. C. Smith^{c,d}, MSc, I.O. Bergfeld^{a,b}, PhD, B.P. de
- 5 Kwaasteniet^e, PhD, J. Luigjes^{a,b}, PhD, J. van Laarhoven^f, MD, P. Notten^f, MD, G. Beute^g, MD, dr. P. van
- 6 den Munckhof^h, MD, P.R. Schuurman^h, PhD, MD, D.A.J.P. Denys^{a,b}, PhD, MD, G.A. van Wingen^{a,b†}, PhD
- 7 *These authors contributed equally to this manuscript.
- 8
- ^a Amsterdam UMC location University of Amsterdam, Department of Psychiatry, Meibergdreef 9,
- 10 Amsterdam, The Netherlands
- 11 ^b Amsterdam Neuroscience, Amsterdam, The Netherlands
- 12 ^c Amsterdam UMC location Vrije Universiteit Amsterdam, Department of Radiology and Nuclear
- 13 Medicine, Boelelaan 1117, Amsterdam, The Netherlands
- 14 ^d Cancer Center Amsterdam, Imaging and Biomarkers, Amsterdam, The Netherlands
- ^e Martini Hospital, Department of Radiology and Nuclear Medicine, Groningen, the Netherlands
- ¹⁶ ^f Department of Psychiatry, ETZ, location Elisabeth, Tilburg, The Netherlands
- 17 ^g Department of Neurosurgery, ETZ, location Elisabeth, Tilburg, The Netherlands
- ^h Amsterdam UMC location University of Amsterdam, Department of Neurosurgery, Amsterdam, the
- 19 Netherlands
- 20
- ¹Corresponding authors at: Amsterdam UMC location University of Amsterdam, Department of
- 22 Psychiatry, Meibergdreef 9, 1105 AZ, Amsterdam, the Netherlands
- 23 E-mail: n.runia@amsterdamumc.nl; l.a.vandemortel@amsterdamumc.nl
- 24 g.a.vanwingen@amsterdamumc.nl
- 25 Telephone: +31208913674

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

26 Abstract

- 28 Depression is associated with abnormal functioning of the reward circuit. Several deep brain
- 29 stimulation (DBS) targets for treatment-resistant depression (TRD) directly modulate white matter
- 30 bundles of the reward circuit. Here we investigated whether baseline reward processing in the brain
- 31 is associated with ventral anterior limb of the internal capsule (vALIC) DBS outcome and whether
- 32 vALIC DBS changes neural activity in the reward circuit.
- 33 We studied fifteen patients with TRD who performed a monetary reward task during functional
- 34 magnetic resonance imaging (fMRI) before vALIC DBS surgery, after DBS parameter optimization, and
- 35 during a sham-controlled crossover phase. DBS devices were switched off during scanning for MRI
- 36 safety reasons. Additionally, fifteen matched healthy controls were investigated twice to account for
- 37 test-retest effects. We investigated brain responses to reward anticipation, loss anticipation, reward
- 38 feedback and loss feedback.
- 39 Results showed that lower baseline nucleus accumbens activation during loss anticipation and higher
- 40 baseline caudate nucleus and midcingulate cortex activation during reward feedback processing
- 41 were associated with worse DBS outcome. No significant changes in reward processing were
- 42 observed following vALIC DBS in comparison to healthy controls or after active compared to sham
- 43 stimulation. Instead, increased middle frontal gyrus responses following DBS to loss feedback was
- 44 associated with better DBS outcome.
- 45 These results suggest that DBS efficacy in TRD is related to individual differences in reward circuit
- 46 functioning at baseline and to changes in middle frontal gyrus responses following DBS.

47 **1. Introduction**

48

49 Treatment-resistant depression (TRD) is commonly defined as a major depressive disorder (MDD) for 50 which two or more prior treatments have failed to achieve clinical response (1). Patients with TRD 51 who do not sufficiently respond to any of the conventional treatment options for MDD, may benefit from deep brain stimulation (DBS). While still in an experimental phase, DBS for severe TRD has 52 53 proved to be a successful treatment, with on average 40% of patients achieving clinical response 54 within one year (2). Common DBS targets for the treatment of TRD include the subcallosal cingulate 55 cortex, ventral anterior limb of the internal capsule (vALIC), and medial forebrain bundle (MFB), of 56 which the latter two are involved in the reward circuit (3-5). Dysfunction of the reward circuit and 57 aberrations in its associated fiber bundles have previously been indicated as a possible cause for the 58 pathological anhedonic states in depressive disorders (6-8). While not much is known about the therapeutic mechanism of vALIC DBS, prolonged stimulation of the vALIC could induce biological 59 changes to its surrounding limbic regions within reward- and affective circuits (9-12). 60 61 Within these circuits, the nucleus accumbens (NAc) is one of the regions that can either

62 directly be stimulated with DBS through the volume of activated tissue (13) or indirectly through 63 connections with the vALIC (14), and could be contributing to the therapeutic changes induced by 64 vALIC DBS. Previous studies have shown that the NAc is a key region in the brain reward circuit (15) 65 and shows abnormal functioning in MDD (16-18). By probing the activity of the NAc during reward 66 anticipation, we have previously shown that NAc reward processing normalizes following vALIC DBS 67 in obsessive-compulsive disorder (9). We therefore hypothesize that such normalization of NAc activity during reward anticipation following vALIC DBS would occur in TRD as well. However, 68 69 whether such normalization in reward anticipation or other measures of reward function occurs in 70 the NAc, and to what extent this also affects other regions related to reward processing has not been 71 investigated previously. Additionally, it is unknown whether baseline reward circuit functioning holds 72 predictive information about future DBS treatment outcome.

73	In this longitudinal functional magnetic imaging (fMRI) study, we investigated reward
74	processing in TRD patients receiving vALIC DBS treatment. Patients underwent fMRI scanning while
75	performing a monetary reward task known to activate the NAc (19-21) before DBS implantation and
76	following surgery and DBS parameter optimization. Matched healthy controls were included and
77	performed the fMRI task at two time points to control for test-retest effects. To assess short-term
78	effects of DBS de-activation after parameter optimization on reward processing, TRD patients also
79	performed the fMRI task after double-blind periods of active and sham stimulation. We investigated
80	the predictive properties of baseline NAc and whole-brain reward processing for DBS treatment
81	response, and assessed longitudinal and active stimulation effects of DBS on reward processing.
82	Additionally, we investigated whether NAc and whole-brain longitudinal changes in reward
83	processing were related to clinical outcome.
84	
85 86	2. Methods 2.1 Patients
86 87	We included patients with TRD as well as healthy controls in a longitudinal study followed by a
88	randomized crossover phase (for patients only). This imaging study was an add-on to a previously
89	reported clinical trial for vALIC DBS in TRD (13) (trial registration number: <u>NTR2118</u>). The study was
90	approved by the medical ethics boards of the two participating hospitals: Academic Medical Center,
91	Amsterdam [AMC] and St Elisabeth Hospital, Tilburg [SEH]. All included patients provided written
92	informed consent.
93	At inclusion, patients had to be aged 18-65 years and have a primary diagnosis of MDD
94	according to the DSM-IV (assessed with a semi-structured clinical interview for DSM-IV disorders), an
95	illness duration of more than 2 years, a 17-item Hamilton Depression Rating Scale (HAM-D-17) score
96	of 18 or higher, and a Global Assessment of Function sore of 45 or lower. Additionally, patients had
97	to be treatment-resistant, defined as a failure of at least two different classes of second-generation
98	antidepressants, one trial of a tricyclic antidepressant, one trial of a tricyclic antidepressant with

99 lithium augmentation, one trial of a monoamine oxidase inhibitor, and six or more sessions of

100 bilateral electroconvulsive therapy. Patients who fulfilled the above criteria and remained stable with 101 maintenance electroconvulsive therapy, but relapsed after discontinuation of that therapy, were also 102 eligible. Patients had to be able to understand the consequences of the procedure (IQ >80), and 103 capable of making choices without coercion. Exclusion criteria were a diagnosis of Parkinson's 104 disease, dementia, epilepsy, bipolar disorder, schizophrenia or history of psychosis unrelated to 105 MDD, antisocial personality disorder, current tic disorder, an organic cause of depression, substance 106 abuse during the past 6 months, unstable physical condition, pregnancy, or general contraindications 107 for surgery. 108 Healthy controls were matched by age, sex, and education level. Their lifetime history of 109 psychiatric illness and that of their first-degree relatives were negative. 110 111 2.2 Treatment 112 Four-contact leads were implanted bilaterally and connected to a neurostimulator (lead: 3389; 113 stimulator: Activa PC/RC, Medtronic, Minneapolis, MN, USA). The electrodes were implanted with 114 the most ventral contact at the core of the NAc and the three more dorsal contacts in the vALIC. 115 Following a three-week recovery period, DBS setting optimization was started. The aim of DBS 116 optimization was to maximize antidepressant effects while minimizing side effects. Standardized 117 optimization included changing active contact points and voltage (ranging from 2.5 to 6.0 V). Pulse 118 width and frequency were kept stable (90 microseconds and 130 or 180 Hz, respectively). 119 Standardized optimization ended after a response (defined as a HAM-D-17 score reduction >=50%) 120 was reached for at least four weeks or after a maximum of 52 weeks. Details on the surgery and 121 vALIC DBS treatment (including parameter optimization) have been described earlier (13). Individual 122 DBS parameter settings after the standardized parameter optimization are provided in 123 Supplementary Table 1.

125 2.3 Study Design

125 126	2.3 Study Design MRI scanning was performed three weeks prior to DBS surgery (baseline), and after DBS parameter
127	optimization (follow-up). The aim was to keep concurrent medication stable during the optimization
128	phase; however, psychiatrists were allowed to make changes for clinical indications (for an overview
129	of psychotropic medications used over time see Supplementary Table 2). Healthy controls were
130	scanned at baseline and after five months. After follow-up, the DBS group entered the double-blind
131	randomized cross-over phase, which consisted of two blocks of one to six weeks during which DBS
132	stimulation was on (active) or off (sham). Patients could be prematurely crossed over to the next
133	phase while blinding was maintained if this was requested by the patient, or if the treating
134	psychiatrist or research team deemed it clinically indicated and the HAM-D-17 score was at least 15.
135	Concurrent medication and DBS settings were kept stable during the crossover phase. Patients again
136	received MRI scans after both active and sham stimulation.
137	The severity of depressive symptoms was measured at each assessment (baseline, follow-up, active,
138	sham) with the HAM-D-17, with higher scores indicating more severe depressive symptoms. A
139	description of the analyses of the HAM-D-17 scores can be found in Supplementary Methods 1.2.
140	
141 142	2.4 fMRI Acquisition and Monetary Reward Task Structural and functional MRI data were collected with a 1.5T Siemens Magnetom Avanto syngo MR
143	scanner with a transmit/receive (Tx/Rx CP) Head Coil. Conform the manufacturer's safety
144	instructions, the DBS devices were switched off during scanning. The devices were turned off just
145	before entering the scanner room and turned back on immediately after leaving the scanner room.
146	For details on the acquisition parameters, see Supplementary Methods 1.3. To probe NAc activation
147	during fMRI data acquisition, patients performed a monetary reward task with an event-related
148	design, which has been shown to consistently activate the NAc (19-21). For a detailed description and
149	visualization of the task, see Supplementary Methods 1.1 and Supplementary Figure 1. In short, the
150	task consisted of 108 trials during which one of three different cues was presented. A reward cue
151	(blue circle) predicted a monetary reward (€0.50/€1.00/€2.00), a neutral cue (brown triangle)

152	predicted no reward/loss, and a loss cue (pink square) predicted a monetary loss (-€0.50/-€1.00/-
153	€2.00). Following a cue, a response window followed where a target (orange exclamation mark) was
154	presented and patients had to respond as quickly as possible with a button press. Successful button
155	presses within the response window led to a win or loss avoidance of the predicted monetary value
156	depending on the presented cue, while a failure to respond within the response window led to no
157	win, or loss of the predicted monetary value depending on the cue. The neutral cue never let to a
158	monetary reward or loss. Subsequently, feedback was shown on screen displaying the amount of
159	money won or lost during the trial as well as the cumulative earnings throughout the task. Reaction
160	times were recorded for each trial. A description of the analysis of the reaction times can be found in
161	Supplementary Methods 1.2.
162	
163 164 165	 2.4 fMRI Data Analysis 2.4.1 Preprocessing Before preprocessing a quality assessment was carried out by manually reviewing MRIQC (22) Image
166	Quality Metrics and visual reports. (f)MRI data were preprocessed using the Statistical Parametric
167	Mapping 12 (SPM12, <u>https://www.fil.ion.ucl.ac.uk/</u>) toolbox in MATLAB R2022a (The Math Works,
168	Inc., 2022). Functional images were realigned to the mean functional image and subsequently slice-
169	time corrected. The realignment parameters were inspected and scans with more than 4 mm (one
170	slice thickness) movement in any direction were excluded from the analyses. Next, the T1-weighted
171	image was coregistered to the mean functional image. The T1-weighted image was then segmented
172	and subsequently the functional images and structural image were normalized into standardized
173	Montreal Neurological Institute (MNI) space and resampled to 3 mm isotropic resolution. To improve
174	the signal-to-noise ratio, the functional images were smoothed using an 8-mm full width at half
175	maximum Gaussian kernel.

177 2.4.2 NAc and Whole-Brain Activity

178 Neural activity during the monetary reward task was estimated with an event-related first-level 179 analysis for each patient at each time-point (baseline, follow-up, active and sham stimulation) using a 180 general linear model. Each type of cue (reward/neutral/loss x monetary value of 0.50/1.00/2.00), 181 each type of feedback (reward, neutral, loss), and the six realignment parameters were modeled as 182 separate regressors. Contrast images were created for reward anticipation (reward cues - neutral 183 cues), loss anticipation (loss cues - neutral cues), reward feedback (reward feedback - neutral feedback), and loss feedback (loss feedback - neutral feedback) and were taken to the second-level 184 185 group analyses. To assess NAc activation, one region-of-interest (ROI) mask for the left and right NAc 186 was created based on the Automated Anatomical Labelling atlas 3 (AAL3) (23). Since the electrodes 187 partially overlap with the NAc in the follow-up data, we created a bilateral electrode mask by first 188 normalizing the voxel intensity of each follow-up scan using the global intensity mean, subsequently 189 thresholding the data to only include voxels with electrode drop-out by selecting an intensity of <0.6, 190 binarizing the data and averaging over time, and then multiplying each individual binary electrode 191 mask to create a bilateral electrode mask averaged over the whole patient sample, which was 192 subsequently multiplied with the bilateral NAc mask. The remaining voxel coverage of the bilateral 193 NAc after removing the electrode artifacts is presented in Supplementary Figure 2. For the 194 longitudinal analyses, we used this mask on both baseline and follow-up data to only include 195 significant differences in NAc regions unaffected by the electrodes.

196

197 2.4.3 fMRI Statistical Analysis

Baseline group-level analyses were performed using SPM12. To assess baseline group differences, we performed a two-sample t-test between DBS patients and healthy controls with age and sex as added covariates for each of the four contrasts on both whole-brain and ROI (NAc) level. To assess whether baseline NAc and whole-brain activity during reward processing is associated with DBS outcome at follow-up, we performed four separate linear regression analyses with the percentage change in HAM-D-17 scores (follow-up - baseline) as the outcome variable and NAc/whole-brain activity during

204 four different contrasts (during reward anticipation, loss anticipation, reward feedback, or loss 205 feedback) as the predictive variable, and age and sex added as covariates. Since the longitudinal 206 change in HAM-D-17 scores violated normality assumptions, we transformed the values by taking the 207 square root of the proportional change in HAM-D-17 scores with an added value of 1 to ensure 208 positive values. For the resulting scores, a value of 1 represents no change, scores <1 represent 209 decreases in HAM-D-17 scores, and scores >1 represent increases in HAM-D-17 scores following DBS. 210 We used voxel-wise inference for ROI analyses in the left and right NAc and corrected for 211 multiple comparisons using a family-wise error (FWE) rate small volume correction (α <0.05). Whole-212 brain activation during reward processing was assessed using cluster-wise inference with a cluster-213 forming threshold of 0.001 and corrected for multiple comparisons using FWE correction (α <0.05). 214 Longitudinal group-level (patients vs. healthy controls and active vs. sham) fMRI analyses 215 were performed using the Sandwich Estimator toolbox for SPM12 (SwE v2.2.0; 216 http://www.nisox.org/Software/SwE) (24) (degrees of freedom type II, small sample adjustment for 217 Wild Bootstrap resampling type C2, 999 bootstraps, unrestricted U-SwE). To assess DBS induced 218 changes in NAc activity from baseline compared to follow-up we performed four separate mixed 219 ANOVAs for each contrast with group (DBS vs. healthy controls) as the between-subjects factor and 220 session (baseline vs. follow-up) as the within-subjects factor. Since the time from baseline to follow-221 up varied greatly within patients (mean=420.78 days, SD=159.15) and between patients and healthy 222 controls (mean=148.00 days, SD=13.74), days since baseline was added as a time-varying covariate to 223 the models. To assess NAc activity following active compared to sham stimulation, we carried out a 224 repeated measures ANOVA with session (active vs. sham) as the within-subjects factor. Due to 225 premature cross-overs, the time between sessions varied between patients (mean=20.63 days, 226 SD=14.26). Therefore, days since baseline as well as the randomization order were added as 227 covariates to the model.

For the longitudinal analyses (baseline vs. follow-up and active vs. sham), we used the SwE
 non-parametric Wild Bootstrap procedure for the ROI analysis with voxel-wise inference and

230	statistical tests across the left and right NAc were corrected for multiple comparisons using a false
231	discovery rate (FDR) small volume correction (α <0.05). Whole brain analyses were performed using
232	the same SwE non-parametric Wild Bootstrap procedure with cluster-wise inference (cluster-forming
233	threshold=0.01). Whole-brain statistical tests were corrected for multiple comparison using FWE
234	correction (α<0.05).
235	To assess whether changes in NAc and whole-brain activity were related to clinical outcome,
236	we performed separate linear regression analyses in SPM12 with the patient group only for each of
237	the four contrasts. For these analyses we modeled the interaction between session (baseline vs.
238	follow-up and active vs. sham) and clinical outcome (transformed percentage change in HAM-D-17
239	scores) while correcting for days since baseline. Results were assessed using the same statistical
240	inference as for the baseline SPM12 analyses described above.
241	
242 243	3. Results In total, twenty-five patients and twenty-two healthy controls were included in the clinical trial, but
244	we were unable to acquire data for each participant at all time points. For a detailed overview of the
245	missing data see Supplementary Table 3. Apart from the missing data, we additionally excluded two
246	patients from our baseline analysis due to unrepresentative and missing HAM-D-17 scores at follow-
247	up, two patients due to insufficient brain coverage during fMRI acquisition, one patient due to
248	missing onset times for the monetary reward task, one healthy control due to excessive head motion
249	(>4 mm), and one healthy control due to a missing HAM-D-17 score at baseline, leaving 15 patients
250	and 18 healthy controls in the baseline analyses. For the follow-up analyses, nine patients and 15
251	healthy controls remained after excluding one patient due to insufficient brain coverage during fMRI,
252	one patient due to missing onset times for the monetary reward task, and two healthy controls due
253	to excessive head motion. We included 11 patients in the active vs. sham analyses after excluding
254	one patient due to excessive head motion.

256 *3.1 Clinical Results*

- 257 Demographic and clinical characteristics are presented in Table 1. Patients and healthy controls
- 258 showed no statistically significant difference in sex, age and estimated IQ. At baseline, patients had
- significantly higher scores than healthy controls on measures of depressive symptom severity in the
- 260 HAM-D-17, MADRS, and IDS-SR (all p<0.001). There was a significant reduction in HAM-D-17 score
- 261 (n=9) from baseline (mean=23.70, 95%CI=18.82-28.51) to follow-up (mean=12.80, 95%CI=7.28-18.28;
- t=-2.375, p=0.033), and patients had a significantly lower HAM-D-17 score (n=11) after active
- stimulation (mean=14.70, 95%CI=10.08-19.37) compared to sham stimulation (mean=22.00,
- 264 95%CI=18.41-25.59; t=-3.380, p=0.0079).

Characteristics	Bas	eline	p-value [†]	Baseline -	- follow-up	p-value [†]	Active-sham
	DBS	НС		DBS	НС		DBS
Sample size	15	18		9	15		11
Sex, No. (%)							
Female	12 (80%)	11 (61%)		8 (87.5%)	9 (60%)		8 (73%)
Male	3 (20%)	7 (39%)	n.s.	1 (12.5%)	6 (40%)	n.s.	3 (27%)
Age at inclusion	······	······					
mean (SD)	52.9 (7.9)	53.2 (8.0)	n.s.	51.6 (8.4)	52.9 (8.3)	n.s.	53.3 (4.9)
median (IQR)**	55.0 (11.0)	55.0 (7.0)		50.0 (6.0)	56.0 (6.0)		
Estimated IQ, mean (SD)	98.0 (15.6)	102.0 (13.5)	n.s.	96.6 (17.4)	104.0 (14.0)	n.s.	96.4 (13.2)
Baseline HAM-D-17 score					i		······
mean (SD)	23.1 (5.6)	0.9 (1.3)	*	23.7 (6.3)	0.7 (1.3)	*	22.4 (6.19)
median (IQR)	23 (8.5)	0.0 (1.0)		23.0 (12.0)	0.0 (1.0)		
Baseline MADRS score							
mean (SD)	34.0 (6.3)	0.8 (1.3)	*	33.9 (6.8)	0.9 (1.4)	*	33.8 (5.8)
median (IQR)	36.0 (7)	0.0 (1.8)		36.0 (7.0)	0.0 (2.0)		
Baseline IDS-SR score							
mean (SD)	49.5 (9.6)	3.2 (2.7)	*	47.9 (9.9)	3.0 (2.3)	*	46.7 (11.5)
median (IQR)	51.0 (14.0)	3.0 (4.0)		47.0 (11.0)	3.0 (4.0)		
Age at MDD onset, mean (SD)						-	
Self-report	28.7 (16.0)	-		29.9 (17.0)	-		30.5 (15.3)
Diagnosis	37.1 (10.4)	-		36.8 (12.1)	-		38.3 (11.8)
No. of past medications							
mean (SD)	10.0 (3.0)	-		10.7 (3.6)	-		10.5 (3.1)
median (IQR)							10.0 (2.5)
No. of past ECT series							
mean (SD)	2.2 (1.1)	-		2.0 (1.2)	-		1.8 (1.1)
median (IQR)	2.0 (2.0)	-			-		1.0 (1.5)
No. of past ECT sessions						-	
mean (SD)	52.8 (49.2)	-		56.7 (60.5)	-		50.2 (55.5)
median (IQR)	47 (30)	-		49.0 (37.0)	-		42.0 (28.5)
Years since MDD onset,		-					
diagnosis, mean (SD)	15.8 (8.8)			14.8 (8.8)	-		15.0 (10.7)
MDD episodes, No. (%)		-					
1	6 (40%)	-		4 (50%)	-		6 (55%)
2	2 (13%)	-		2 (25%)	-		3 (27%)
>2	7 (47%)	-		2 (25%)	-		2 (18%)

Abbreviations: DBS, Deep Brain Stimulation; HC, healthy controls; SD, standard deviation; IQ, intelligence quotient; HAM-D, Hamilton Rating Scale for Depression; MADRS, Montgomery-Åsberg Depression Rating Scale; IDS-SR, Inventory of Depressive Symptomatology-Self-report; MDD, major depressive disorder; ECT, electroconvulsive therapy.

+ p-values were obtained with appropriate parametric and non-parametric tests.

* Significant differences between patients and healthy controls (p<0.001).

** median indicated when normality assumptions were violated.

266 3.2 Behavioral Results

267	For both comparative analyses there was a significant main effect of condition for reaction time
268	(baseline vs. follow-up: F(2,107.96)=3.942, p=0.008; sham vs. active: F(2,48)=5.018, p=0.01), with
269	average reaction times after reward and loss cues being significantly shorter compared to average
270	reaction times after neutral cues. Additionally, the baseline vs. follow-up analysis revealed a
271	significant interaction effect between group and session (F(1,112.42)=7.038, p= 0.009). Post-hoc
272	comparisons showed that there was no significant difference in average reaction times between
273	patients and healthy controls at baseline. However, average reaction times in healthy controls
274	significantly decreased at follow-up compared to baseline, whereas there was no significant
275	difference in patients. There were no significant interaction effects with condition (p>0.05). There
276	was also no significant difference in average reaction times after active compared to sham
277	stimulation (p>0.05) and no significant interaction between those sessions and condition (p>0.05).
278	
279 280	3.3 fMRI results 3.3.1 Baseline
280 281	Group comparisons did not show any statistically significant differences between patients and
282	healthy controls at baseline in NAc and whole-brain activity during reward anticipation, loss
283	anticipation, reward feedback, or loss feedback (p _{fwe-corrected} >0.05).
284	Regression analyses within the patient group between baseline activity and DBS outcome
285	showed that lower NAc activity during loss anticipation was significantly associated with worse
286	outcome (p _{fwe-corrected} =0.025, see Figure 1). Additionally, we found that higher midcingulate (MNI: 18,-
287	1,35; cluster extent: 40 voxels; p _{fwe-corrected} =0.029, see Figure 2) and caudate nucleus (MNI: -
288	3,17,17;cluster extent: 72 voxels; p _{fwe-corrected} =0.002, see Figure 3) activity in reward feedback was
289	significantly associated with worse outcome.
290	One of the patients had an atypical large increase in HAM-D-17 score following DBS
291	combined with largely deviating brain responses during reward processing at baseline. The HAM-D-
292	17 change score of this patient was statistically not deemed to be an outlier. Nonetheless, we

293 investigated whether the associations between activity in these clusters and DBS outcome remained 294 significant without this patient. Within the clusters, associations remained significant for both the 295 caudate nucleus (p=0.02) and midcingulate (p=0.02), but not for the NAc (p>0.05). However, the 296 clusters did not remain statistically significant when we reperformed the whole-brain analyses after 297 excluding this patient. 298 3.3.2 Baseline vs. Long-Term Follow-up 299 Neither the whole-brain analysis nor the NAc ROI-analysis showed significant session x group 300 interaction effects (p_{FWE/FDR-corrected}>0.05) for any of the four different contrasts. None of the contrasts 301 showed a significant effect of session on the whole-brain level (p_{FWE-corrected}>0.05) or specifically in the 302 NAc (p_{FDR-corrected}>0.05). Additionally, no significant main effects of group were found after whole-303 brain analysis (p_{FWE-corrected}>0.05). However, ROI-analysis of the NAc showed a trend towards a 304 significant main effect of group during reward feedback (left: p_{FDR-corrected}=0.073, right: p_{FDR}-305 corrected=0.073). An exploratory post-hoc comparison showed that patients exhibited decreased right 306 and left NAc activity during reward feedback compared to healthy controls (left: p_{FDR-corrected}=0.039, 307 right: p_{FDR-corrected}=0.039). The other contrasts did not show significant main effects of group in the 308 NAc (p_{FDR-corrected}>0.05). 309 One patient in the longitudinal data did not have a representative HAM-D-17 score at follow 310 up, and we thus assessed if activity changes over time were dependent on the clinical outcome 311 within the group of eight remaining patients. Whole-brain analysis on the activity change (follow-up 312 - baseline) and DBS outcome revealed that an increase in left middle frontal gyrus (MFG) activity 313 during loss feedback was significantly associated with better clinical outcome (MNI: -39,11,32; cluster 314 extent: 32 voxels; pFWE-corrected=0.037, see Figure 4). NAc ROI-analysis for loss feedback did not show 315 an association between activity change and clinical outcome (pFWE-corrected>0.05), and none of the 316 other contrasts showed any significant associations between activity change in the NAc or on the whole-brain level and clinical outcome (p_{FWE-corrected}>0.05). 317 318

319 320	<i>3.3.3 Active vs. Sham DBS</i> Whole-brain analysis and NAc ROI-analysis of the cross-over phase (active vs. sham) showed no
321	significant effects of session (p _{FWE/FDR-corrected} >0.05) for any of the different contrasts. Additionally,
322	there were no significant associations between activity change in the NAc or on the whole-brain level
323	and clinical outcome for any of the four contrasts (p_{FWE} >0.05).
324	
325	
326 327	4. Discussion This study aimed to assess the effect of vALIC DBS on reward processing in the NAc and on the
328	whole-brain level, and to study both baseline and longitudinal associations between brain activity
329	during reward processing and DBS outcome. The results showed that higher caudate nucleus and
330	midcingulate cortex activation during reward feedback processing and lower NAc activation during
331	loss anticipation were associated with worse DBS outcome. Although DBS resulted in a significant
332	decrease in depressive symptoms, we found no significant effect of DBS on changes in reward
333	processing when the whole group of patients was compared to healthy controls, nor after a period of
334	active compared to sham stimulation. Though within the patient group, we observed a significant
335	association between increased MFG response to loss feedback following DBS and a better DBS
336	outcome in patients.
337	The brain regions found to be associated with DBS outcome (the NAc, midcingulate cortex,
220	

and the caudate nucleus) have previously shown to be involved in reward processes and rewardbased decision making (25-27). In addition, these regions have previously been implicated in the neurobiology of TRD (28-30), and have consistently shown hypoactivity during reward feedback in MDD and relations to anhedonia (17, 31, 32). While we did not find a significant difference in brain activity in these regions between patients and controls at baseline, our findings imply that functional variation in the NAc, midcingulate cortex, and caudate nucleus within the patient group may still be relevant for the outcome of DBS.

345 Despite a significant reduction in depression symptoms after (active) DBS, patients did not show changes in brain reward circuit regions following long-term DBS or after active compared to 346 347 sham stimulation. This result is in contrast with our previous study in obsessive-compulsive disorder, 348 in which we reported that DBS restores aberrant NAc function during reward processing (9). This 349 discrepancy could possibly be explained by different underlying biological disease mechanisms, but 350 may also be due to differences in study design, as the study in obsessive-compulsive disorder 351 compared patients following one year of active stimulation and after one week of DBS cessation. 352 Nonetheless, since a large body of literature suggests that MDD is associated with aberrant reward 353 processing in the brain (e.g. 8, 17, 33) and we specifically aimed to target the reward circuit by 354 stimulation of the vALIC, it was surprising to find no DBS induced changes in reward processing. As 355 we did not include a scale that specifically measured anhedonia, we cannot be entirely sure that 356 vALIC DBS reduced anhedonia. Since anhedonia is specifically linked to activity in the reward circuit 357 (e.g. 32), this could explain why we did not find reward circuit modulation after DBS. However, given the substantial reduction in depressive symptoms in our sample, it seems unlikely that DBS did not 358 359 have any influence on anhedonia.

360 But while there were no significant changes over time in reward processing when we 361 compared the entire group of DBS patients to healthy controls, we did find an association between 362 MFG activity during loss feedback and DBS outcome. Specifically, our results imply that MFG activity 363 increases following DBS lead to better DBS outcome. The MFG has previously shown involvement in 364 reward and loss processing (34, 35), may genetically and functionally be involved in depression (17, 36), and is an important target for repetitive transcranial magnetic stimulation treatment of 365 366 depression (37). While we found this association in only a small group of patients and thus requires 367 further investigation, it corroborates previous findings on the involvement of the MFG in depression 368 and its clinical treatments.

Overall, we observed quite remarkable variation in recorded brain responses during the
 various reward conditions. While this facilitated the detection of associations between neural

371 responses and DBS outcome, we did not find overall differences between DBS patients and healthy 372 controls at baseline. The high variation recorded in the small sample of this study may have limited 373 our power in detecting group differences. Additionally, one of the patients in this study had a 374 deviating HAM-D-17 change score combined with more extreme brain responses during reward 375 processing, which was largely driving the associations between brain responses during reward 376 processing and DBS outcome. Although these associations remained significant in the caudate 377 nucleus and midcingulate without this patient, the association between NAc responses to loss 378 anticipation and DBS outcome disappeared, and we were not able to detect significant clusters when 379 removing the patient from the analyses. While this limits the robustness of our findings, it could also 380 be that smaller associations were not detectable with the reduced power after removing this patient 381 altogether. Nonetheless, the deviating HAM-D-17 change score of this patient was not a statistical 382 outlier and high variation in responses to reward cues is common in regions such as the NAc in MDD, 383 with the most deviating responses correlating with anhedonia and suicidal ideation severity (38). To 384 the best of our knowledge, no study has previously investigated the role of brain reward circuit 385 functioning as a predictor for DBS outcome. Thus, we cannot conclude whether the recorded 386 responses to different reward cues in this patient was an exception and significant outlier, or 387 whether this largely deviating response holds clinical relevance for associations with DBS outcome. 388 An important limitation of this study is the limited number of patients that could be included 389 in the longitudinal analysis, which may have affected our results and their replicability in similar

future studies (39). This study was part of a randomized controlled clinical trial, and the required sample size was calculated based on the required power to determine the therapeutic efficacy of vALIC DBS (13). The effects of DBS on fMRI measures were secondary outcomes of the study for which we unfortunately had less data (and thus power) to detect reward processing changes when compared to healthy controls. Due to this lack of power, this study also did not control for additional factors such as medication use. Nevertheless, the sample size is relatively large for an fMRI study with TRD patients undergoing DBS. Future studies powered with fMRI outcomes as one of the

397 primary outcome measures, have to reveal whether DBS may have smaller effects on reward 398 processing and to investigate how clinical factors affect the outcome of DBS and its effects on reward 399 processing. Another limitation is that we were unable to investigate acute DBS effects on brain 400 regions involved in reward processing as the DBS systems had to be switched off during scanning 401 due to safety reasons. Future studies using DBS systems which can be safely turned on during 402 scanning could determine whether acute effects of DBS on reward processing in the brain play a role 403 in its working mechanism. 404 In summary, we found associations between baseline activity in the midcingulate cortex, 405 caudate nucleus, and NAc during reward processing and DBS outcome in TRD, but no general shortterm or long-term effects of DBS on reward processing compared to healthy controls. Instead, we 406 407 observed a significant association between MFG response increases to loss feedback and a better 408 DBS outcome. These findings have to be replicated in larger samples to determine whether reward 409 processing could be relevant for our understanding and optimization of DBS treatment in patients 410 with TRD.

411

412 Acknowledgments

Funding: This investigator-initiated study was funded by Medtronic Inc (25 DBS systems, in kind) and
a research grant from ZonMw (nr. 171201008).

415

416 **Competing interests**

The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: This investigator-initiated study was funded by Medtronic Inc (25 DBS systems, in kind) and a grant from ZonMw (nr. 171201008). The funders had no role in the design, execution, and analysis of the study, nor in writing of the manuscript or the decision to publish. Nora Runia, Isidoor Bergfeld, Pepijn van den Munckhof, P. Richard Schuurman, Damiaan Denys, and Guido van Wingen currently execute an investigator-initiated clinical trial on deep brain stimulation for depression, which is funded by Boston Scientific (24 DBS systems in kind) and a grant medRxiv preprint doi: https://doi.org/10.1101/2023.12.07.23299640; this version posted November 1, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in

perpetuity. It is made available under a CC-BY 4.0 International license .

- 424 of ZonMw (nr. 636310016). P. Richard Schuurman acts as consultant for Boston Scientific and
- 425 Medtronic on educational events. All other authors do not declare any conflicts of interest.

426

- 427 (Supplementary information is available at MP's website)
- 428

References 429

430

431 Gaynes BN, Lux L, Gartlehner G, Asher G, Forman-Hoffman V, Green J, et al. Defining 1. 432 treatment-resistant depression. Depression and anxiety. 2020;37(2):134-45.

433 Bergfeld IO, Figee M. Deep Brain Stimulation for Depression. Fundamentals and Clinics of 2. 434 Deep Brain Stimulation: Springer; 2020. p. 279-90.

435 3. Coenen VA, Schlaepfer TE, Goll P, Reinacher PC, Voderholzer U, Van Elst LT, et al. The medial 436 forebrain bundle as a target for deep brain stimulation for obsessive-compulsive disorder. CNS 437 spectrums. 2017;22(3):282-9.

438 4. Coenen VA, Schlaepfer TE, Maedler B, Panksepp J. Cross-species affective functions of the 439 medial forebrain bundle—Implications for the treatment of affective pain and depression in humans. 440 Neuroscience & Biobehavioral Reviews. 2011;35(9):1971-81.

441 5. Coenen VA, Schlaepfer TE, Sajonz B, Döbrössy M, Kaller CP, Urbach H, Reisert M.

442 Tractographic description of major subcortical projection pathways passing the anterior limb of the internal capsule. Corticopetal organization of networks relevant for psychiatric disorders. 443

444 NeuroImage: Clinical. 2020;25:102165.

445 6. Dillon DG, Gonenc A, Belleau E, Pizzagalli DA. Depression is associated with dimensional and 446 categorical effects on white matter pathways. Depression and anxiety. 2018;35(5):440-7.

447 7. Henderson SE, Johnson AR, Vallejo AI, Katz L, Wong E, Gabbay V. A preliminary study of white 448 matter in adolescent depression: relationships with illness severity, anhedonia, and irritability. 449 Frontiers in psychiatry. 2013;4:152.

450 8. Höflich A, Michenthaler P, Kasper S, Lanzenberger R. Circuit mechanisms of reward, 451 anhedonia, and depression. International Journal of Neuropsychopharmacology. 2019;22(2):105-18.

452 9. Figee M, Luigjes J, Smolders R, Valencia-Alfonso C-E, Van Wingen G, De Kwaasteniet B, et al. 453 Deep brain stimulation restores frontostriatal network activity in obsessive-compulsive disorder. 454 Nature neuroscience. 2013;16(4):386-7.

455 10. Park HR, Kim IH, Kang H, McCairn KW, Lee DS, Kim B-N, et al. Electrophysiological and imaging evidence of sustained inhibition in limbic and frontal networks following deep brain 456 457 stimulation for treatment refractory obsessive compulsive disorder. PLoS One. 2019;14(7):e0219578.

458 11. Runia N, Bergfeld IO, de Kwaasteniet BP, Luigjes J, van Laarhoven J, Notten P, et al. Deep
459 brain stimulation normalizes amygdala responsivity in treatment-resistant depression. Molecular
460 psychiatry. 2023;28(6):2500-7.

Schlaepfer TE, Bewernick BH, Kayser S, Hurlemann R, Coenen VA. Deep brain stimulation of
the human reward system for major depression—rationale, outcomes and outlook.
Neuropsychopharmacology. 2014;39(6):1303-14.

Bergfeld IO, Mantione M, Hoogendoorn ML, Ruhé HG, Notten P, van Laarhoven J, et al. Deep
brain stimulation of the ventral anterior limb of the internal capsule for treatment-resistant
depression: a randomized clinical trial. JAMA psychiatry. 2016;73(5):456-64.

467 14. Gutman DA, Holtzheimer PE, Behrens TE, Johansen-Berg H, Mayberg HS. A tractography
468 analysis of two deep brain stimulation white matter targets for depression. Biological psychiatry.
469 2009;65(4):276-82.

470 15. Bayassi-Jakowicka M, Lietzau G, Czuba E, Steliga A, Waśkow M, Kowiański P. Neuroplasticity
471 and Multilevel System of Connections Determine the Integrative Role of Nucleus Accumbens in the
472 Brain Reward System. Int J Mol Sci. 2021;22(18).

473 16. Liu R, Wang Y, Chen X, Zhang Z, Xiao L, Zhou Y. Anhedonia correlates with functional
474 connectivity of the nucleus accumbens subregions in patients with major depressive disorder.
475 NeuroImage: Clinical. 2021;30:102599.

476 17. Yang X, Su Y, Yang F, Song Y, Yan J, Luo Y, Zeng J. Neurofunctional mapping of reward
477 anticipation and outcome for major depressive disorder: a voxel-based meta-analysis. Psychological
478 medicine. 2022;52(15):3309-22.

479 18. Zhou B, Chen Y, Zheng R, Jiang Y, Li S, Wei Y, et al. Alterations of static and dynamic
480 functional connectivity of the Nucleus Accumbens in patients with Major Depressive Disorder.
481 Frontiers in Psychiatry. 2022;13:877417.

482 19. Knutson B, Adams CM, Fong GW, Hommer D. Anticipation of increasing monetary reward
 483 selectively recruits nucleus accumbens. Journal of Neuroscience. 2001;21(16):RC159-RC.

484 20. Knutson B, Fong GW, Adams CM, Varner JL, Hommer D. Dissociation of reward anticipation
485 and outcome with event-related fMRI. Neuroreport. 2001;12(17):3683-7.

486 21. Knutson B, Westdorp A, Kaiser E, Hommer D. FMRI visualization of brain activity during a
487 monetary incentive delay task. Neuroimage. 2000;12(1):20-7.

488 22. Esteban O, Birman D, Schaer M, Koyejo OO, Poldrack RA, Gorgolewski KJ. MRIQC: Advancing
489 the automatic prediction of image quality in MRI from unseen sites. PloS one. 2017;12(9):e0184661.

490 23. Rolls ET, Huang C-C, Lin C-P, Feng J, Joliot M. Automated anatomical labelling atlas 3.
491 Neuroimage. 2020;206:116189.

492 24. Guillaume B, Hua X, Thompson PM, Waldorp L, Nichols TE, Initiative AsDN. Fast and accurate
 493 modelling of longitudinal and repeated measures neuroimaging data. NeuroImage. 2014;94:287-302.

494 25. Balleine BW, Delgado MR, Hikosaka O. The role of the dorsal striatum in reward and decision-495 making. Journal of Neuroscience. 2007;27(31):8161-5.

496 26. Burton AC, Nakamura K, Roesch MR. From ventral-medial to dorsal-lateral striatum: neural
497 correlates of reward-guided decision-making. Neurobiology of learning and memory. 2015;117:51-9.

498 27. Vogt BA. Midcingulate cortex: structure, connections, homologies, functions and diseases.499 Journal of chemical neuroanatomy. 2016;74:28-46.

Amiri S, Arbabi M, Kazemi K, Parvaresh-Rizi M, Mirbagheri MM. Characterization of brain
 functional connectivity in treatment-resistant depression. Progress in Neuro-Psychopharmacology
 and Biological Psychiatry. 2021:110346.

Sun J, Ma Y, Guo C, Du Z, Chen L, Wang Z, et al. Distinct patterns of functional brain network
integration between treatment-resistant depression and non treatment-resistant depression: A
resting-state functional magnetic resonance imaging study. Progress in Neuro-Psychopharmacology
and Biological Psychiatry. 2023;120:110621.

Wu QZ, Li DM, Kuang WH, Zhang TJ, Lui S, Huang XQ, et al. Abnormal regional spontaneous
neural activity in treatment-refractory depression revealed by resting-state fMRI. Human brain
mapping. 2011;32(8):1290-9.

510 31. Pizzagalli DA, Holmes AJ, Dillon DG, Goetz EL, Birk JL, Bogdan R, et al. Reduced caudate and
511 nucleus accumbens response to rewards in unmedicated individuals with major depressive disorder.
512 American Journal of Psychiatry. 2009;166(6):702-10.

32. Wacker J, Dillon DG, Pizzagalli DA. The role of the nucleus accumbens and rostral anterior
cingulate cortex in anhedonia: integration of resting EEG, fMRI, and volumetric techniques.
Neuroimage. 2009;46(1):327-37.

S16 33. Zhang W-N, Chang S-H, Guo L-Y, Zhang K-L, Wang J. The neural correlates of reward-related
processing in major depressive disorder: a meta-analysis of functional magnetic resonance imaging
studies. Journal of affective disorders. 2013;151(2):531-9.

51934.Dugré JR, Dumais A, Bitar N, Potvin S. Loss anticipation and outcome during the Monetary520Incentive Delay Task: a neuroimaging systematic review and meta-analysis. PeerJ. 2018;6:e4749.

52135.Knutson B, Bhanji JP, Cooney RE, Atlas LY, Gotlib IH. Neural responses to monetary incentives522in major depression. Biological psychiatry. 2008;63(7):686-92.

523 36. Liu X, Hou Z, Yin Y, Xie C, Zhang H, Zhang H, et al. CACNA1C gene rs11832738 polymorphism
524 influences depression severity by modulating spontaneous activity in the right middle frontal gyrus in
525 patients with major depressive disorder. Frontiers in Psychiatry. 2020;11:73.

526 37. Pommier B, Vassal F, Boutet C, Jeannin S, Peyron R, Faillenot I. Easy methods to make the neuronavigated targeting of DLPFC accurate and routinely accessible for rTMS. Neurophysiologie 527 528 Clinique/Clinical Neurophysiology. 2017;47(1):35-46.

529 38. Misaki M, Suzuki H, Savitz J, Drevets WC, Bodurka J. Individual variations in nucleus accumbens responses associated with major depressive disorder symptoms. Scientific reports. 530 531 2016;6(1):21227.

532 39. Turner BO, Paul EJ, Miller MB, Barbey AK. Small sample sizes reduce the replicability of task-533 based fMRI studies. Communications biology. 2018;1(1):62.

534

medRxiv preprint doi: https://doi.org/10.1101/2023.12.07.23299640; this version posted November 1, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

It is made available un	nder a CC-BY	4.0 International	license.

526			
	_	2	
		-	

537	Figure 1. Negative association between nucleus accumbens response during loss anticipation at
538	baseline and DBS outcome. Results from ROI-based regression analysis revealed that higher
539	responses during loss anticipation led to a better outcome in vALIC DBS (p _{FWE-corrected} =0.025).
540	HAMD=Hamilton-Depression Rating Scale.
541	
542	
543	Figure 2: Positive association between right midcingulate response to reward feedback at baseline
544	and DBS outcome. Whole-brain regression analysis revealed a statistically significant cluster in the
545	right midcingulate gyrus where lower responses to reward feedback led to a better outcome in vALIC
546	DBS (p _{FWE-corrected} =0.029). HAMD=Hamilton-Depression Rating Scale.
547	
548	
549	Figure 3: Positive association between right caudate nucleus response to reward feedback at
550	baseline and DBS outcome. Whole-brain regression analysis revealed a statistically significant cluster
551	in the right caudate nucleus, where lower responses to reward feedback led to a better outcome in
552	vALIC DBS (p _{FWE-corrected} =0.002). HAMD=Hamilton-Depression Rating Scale.
553	
554	
555	Figure 4: Association between longitudinal changes in the left middle frontal gyrus response to loss
556	feedback and DBS outcome. Whole-brain regression analysis revealed an association between
557	changes in the left MFG response to loss feedback and HAM-D-17 change following vALIC DBS
558	treatment, with an increase in left MFG response to loss feedback being associated with higher
559	clinical improvement (p _{FWE-corrected} =0.037). HAMD=Hamilton Depression Rating Scale, MFG=middle
560	frontal gyrus.
561	







